PT Bundamedik (BMHS) Fundamentals 2026 — P/E 168.1x, Revenue Analysis | SniperIQ
PT Bundamedik (BMHS) is a ID-listed Healthcare company in Medical - Care Facilities with a market capitalization of Rp1.55T, trading at Rp180.00 on the JKT. This SniperIQ fundamentals page covers PT Bundamedik's valuation (P/E 168.1x, P/B 0.8x), profitability (net margin 0.6%), revenue (Rp1.61T in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is PT Bundamedik's market cap?
PT Bundamedik (BMHS) has a market capitalization of approximately Rp1.55T, trading at Rp180.00 on the JKT. Market cap moves with the live share price.
What is PT Bundamedik's P/E ratio?
PT Bundamedik's trailing twelve-month P/E ratio is 168.1x, with a price-to-book (P/B) of 0.8x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is PT Bundamedik?
PT Bundamedik runs a net profit margin of 0.6%, a gross margin of 41.1%, and an operating margin of 6.7%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does PT Bundamedik generate?
PT Bundamedik reported revenue of Rp1.61T for fiscal year 2025, with net income of Rp12.4B and earnings per share (EPS) of 1.66. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does PT Bundamedik pay a dividend?
PT Bundamedik offers a trailing dividend yield of about 0.6%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is PT Bundamedik financially healthy?
PT Bundamedik carries a debt-to-equity ratio of 0.72x and a current ratio of 1.70x, with a market beta of -0.19. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is PT Bundamedik a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For PT Bundamedik (BMHS) the key facts are: market cap Rp1.55T, P/E 168.1x, revenue Rp1.61T, 52-week range 143-246. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track PT Bundamedik's full fundamentals live
Get PT Bundamedik's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.